BioCentury | Aug 17, 2017
Finance

Built to purpose

...Biopharma Inc. The Medicines Co. (NASDAQ:MDCO) Atlas Venture Neurology Single asset $8.8 $54.7 2012 2015 Sideris Pharmaceuticals Inc....
...after a $32 million series A investment -- the MPM-led deal with Novartis AG for Sideris Pharmaceuticals Inc....
BioCentury | Jan 13, 2014
Company News

Sideris Pharmaceuticals management update

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Hired: Gregory Berk as president, CMO and a director, formerly CMO of Bind Therapeutics Inc. WIR Staff...
BioCentury | Oct 28, 2013
Company News

Sideris Pharmaceuticals board of directors update

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Appointed: Ansbert Gadicke, managing director at MPM Capital; Doug Reed, general partner at Hatteras Venture Partners; and Kazumi Shiosaki, managing director at MPM WIR Staff Hematology...
BioCentury | Oct 28, 2013
Financial News

Sideris Pharmaceuticals completes venture financing

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Date completed: 10/22/13 Type: Venture financing Raised: $32 million Investors: MPM Capital; Hatteras Venture Partners; Osage University Partners WIR Staff Hematology...
BioCentury | Oct 28, 2013
Finance

Paying the iron price

...A group of VCs and Novartis AG (NYSE:NVS; SIX:NOVN) are betting that Sideris Pharmaceuticals Inc. 's iron chelator...
BioCentury | Oct 28, 2013
Company News

Sideris Pharmaceuticals, Novartis deal

...with Phase I testing slated to start next year. The companies declined to disclose details. Sideris Pharmaceuticals Inc....
BioCentury | Oct 23, 2013
Top Story

Sideris raises $32M, grants Novartis option

Sideris Pharmaceuticals Inc. (Boston, Mass.) raised $32 million in a series A round led by new investor MPM Capital. New investors Hatteras Venture Partners and Osage University Partners also participated. Sideris' SP-420 is an oral...
Items per page:
1 - 7 of 7
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Biopharma Inc. The Medicines Co. (NASDAQ:MDCO) Atlas Venture Neurology Single asset $8.8 $54.7 2012 2015 Sideris Pharmaceuticals Inc....
...after a $32 million series A investment -- the MPM-led deal with Novartis AG for Sideris Pharmaceuticals Inc....
BioCentury | Jan 13, 2014
Company News

Sideris Pharmaceuticals management update

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Hired: Gregory Berk as president, CMO and a director, formerly CMO of Bind Therapeutics Inc. WIR Staff...
BioCentury | Oct 28, 2013
Company News

Sideris Pharmaceuticals board of directors update

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Appointed: Ansbert Gadicke, managing director at MPM Capital; Doug Reed, general partner at Hatteras Venture Partners; and Kazumi Shiosaki, managing director at MPM WIR Staff Hematology...
BioCentury | Oct 28, 2013
Financial News

Sideris Pharmaceuticals completes venture financing

Sideris Pharmaceuticals Inc. , Boston, Mass. Business: Hematology Date completed: 10/22/13 Type: Venture financing Raised: $32 million Investors: MPM Capital; Hatteras Venture Partners; Osage University Partners WIR Staff Hematology...
BioCentury | Oct 28, 2013
Finance

Paying the iron price

...A group of VCs and Novartis AG (NYSE:NVS; SIX:NOVN) are betting that Sideris Pharmaceuticals Inc. 's iron chelator...
BioCentury | Oct 28, 2013
Company News

Sideris Pharmaceuticals, Novartis deal

...with Phase I testing slated to start next year. The companies declined to disclose details. Sideris Pharmaceuticals Inc....
BioCentury | Oct 23, 2013
Top Story

Sideris raises $32M, grants Novartis option

Sideris Pharmaceuticals Inc. (Boston, Mass.) raised $32 million in a series A round led by new investor MPM Capital. New investors Hatteras Venture Partners and Osage University Partners also participated. Sideris' SP-420 is an oral...
Items per page:
1 - 7 of 7